Can postmenopausal estrogen changes reduce hepatic LDL receptor activity and raise LDL cholesterol?

During the transition to menopause, the significant decline in circulating estradiol initiates a distinct atherogenic lipid shift, characterized by an elevation in low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB).

Mechanistic regulation of LDL receptors

• Transcriptional downregulation: Estrogen receptor alpha (ERα) signaling normally stimulates LDLR gene transcription by interacting with the Sp1 transcription factor and promoting sterol regulatory element-binding protein 2 (SREBP2) expression. Estrogen deficiency diminishes this transcriptional drive, reducing hepatic LDL receptor (LDLR) synthesis.
• Accelerated receptor degradation: Estrogen signaling through ERα and G protein-coupled estrogen receptor (GPER) suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9). Postmenopausal estrogen loss removes this suppression, elevating PCSK9 levels which target cell-surface LDLR for lysosomal degradation.

Clinical and kinetic evidence

• Impaired clearance: Kinetic studies demonstrate that reduced hepatic LDLR activity directly decreases the fractional catabolic rate (clearance) of LDL particles rather than increasing their synthesis. This impaired clearance leads to the accumulation of atherogenic circulating LDL-C.
• Hormonal reversibility: Clinical trials show that menopausal hormone therapy (MHT) reverses these effects by restoring hepatic LDLR activity and accelerating lipid clearance. However, standard lipid-lowering therapies remain preferred for primary lipid management due to MHT-associated thromboembolic and cardiovascular risks.

Bottom line

• Postmenopausal estrogen deficiency directly reduces hepatic LDL receptor activity through diminished SREBP2-mediated transcription and elevated PCSK9-mediated degradation, impairing lipid clearance and elevating circulating LDL-C.